Scorpion Therapeutics

We are pleased to share clinical program updates for our mutant-selective PI3Ka inhibitor STX-478 that underscore our commitment to advancing precision oncology. At #SABCS24, we are presenting updated data from our Phase 1/2 study of STX-478. The results highlight robust PI3Kα pathway inhibition, favorable safety, and a clear dose-response relationship. These findings reinforce STX-478’s potential to transform outcomes for patients with a variety of solid tumors. Additionally, we have entered into a new clinical trial collaboration with #Pfizer to evaluate Pfizer’s investigative selective-CDK4 inhibitor, in combination with STX-478 and fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer in the frontline metastatic setting. Together with our partners, we are dedicated to shaping the future of cancer therapy by delivering innovative, targeted solutions for those who need them most. Learn more: https://bit.ly/4fbaw13

We’re headed to San Antonio and look forward to sharing clinical data from our Phase 1/2 STX-478 trial during a Poster Spotlight Session (PS7-02) on Wed, Dec 11 at #SABCS24. Join us to uncover insights shaping the future of #PrecisionOncology. We hope to see you there! Check out our session details: https://bit.ly/3D3Erux

Today, we are one step closer to potentially improving the lives of patients living with non-small cell lung cancer (#NSCLC). We’re excited to announce that the first patient has been treated in a Phase 1/2 first-in-human dose-escalation, dose-optimization and dose-expansion trial of STX-241, a highly differentiated, orally bioavailable, highly selective tyrosine kinase inhibitor targeting EGFR Exon 19 or 21 mutations with the co-occurring C797S mutation. STX-241 was discovered by Scorpion and is the second program being developed in collaboration with Pierre Fabre Laboratories. Learn more: https://bit.ly/3Nf3PzB   #NSCLC #PrecisionOncology

Scorpion is honored to support #BreastCancerAwarenessMonth and share the promising results from our recent clinical study presented at #ESMO. Our Phase 1/2 trial of STX-478 demonstrates potentially best-in-class PI3Kα inhibition, showing a 23% overall response rate in HR+/HER2- metastatic breast cancer, and significant tumor reductions in patients with advanced solid tumors. Our early, differentiated signals of monotherapy efficacy compare favorably to other pathway inhibitors. This milestone reflects our unwavering commitment to improving patients' lives through next-generation precision oncology. Learn more about our findings and ongoing efforts: https://bit.ly/3Y4iB25

Today at #ESMO2024, we announced initial clinical data from our Phase 1/2 Trial of STX-478 demonstrating potentially best-in-class mutant-selective PI3Kα inhibition for the treatment of advanced solid tumors Learn more: https://bit.ly/3MLH4CX

At Scorpion, we're committed to giving back to our local communities and making a positive impact. Recently, our employees came together to build children's bikes for donation to East Boston Social Centers and the Redwood City Pal Center. This community service event was more than just team building; it was about supporting local organizations and bringing joy to children in need. We're grateful to all the Scorpions who made this event a success. Let's continue to support and uplift our communities together.

🚀 Thrilled to announce a $150 million Series C financing! We are grateful to co-leads Frazier Life Sciences and Lightspeed Venture Partners, and all our new and existing investors. This funding will significantly advance our precision oncology pipeline, including key programs STX-478, STX-721 and STX-241. Discover how this supports our mission to push the boundaries of precision oncology https://bit.ly/4d36l6U

This week, we celebrated a special milestone - our company anniversary. It's been four years of hard work and dedication, and we’re proud of our achievements that include: 1. Advancing three compounds into development 2. Building a fully-integrated chemistry discovery engine 3. Growing our Scorpion teams in Boston and South San Francisco 4. Presenting a Trial-In-Progress at SABCS alongside Dr. Alberto Montero about our ongoing Phase 1/2 clinical study of STX-478 Here’s to many years ahead of working to deliver transformative medicines to patients!

It's an exciting day for the future of drug discovery in cancer. Scorpion team members alongside Co-Founder Liron Bar-Peled and scientists at Mass General Brigham authored a new study published in Cell, which looked to uncover which proteins may be druggable across cancer. These findings further attest to our commitment to developing the next generation of targeted cancer therapies and transforming the lives of patients. Read more about the study here: https://lnkd.in/emW-cUDz

This week, we celebrated a special milestone - our company anniversary. It's been four years of hard work and dedication, and we’re proud of our achievements that include: 1. Advancing three compounds into development 2. Building a fully-integrated chemistry discovery engine 3. Growing our Scorpion teams in Boston and South San Francisco 4. Presenting a Trial-In-Progress at SABCS alongside Dr. Alberto Montero about our ongoing Phase 1/2 clinical study of STX-478 Here’s to many years ahead of working to deliver transformative medicines to patients!